Search Results - "Landherr, Laszlo"

Radiotherapy of Breast Cancer-Professional Guideline 1st Central-Eastern European Professional Consensus Statement on Breast Cancer by Polgár, Csaba, Kahán, Zsuzsanna, Ivanov, Olivera, Chorváth, Martin, Ligačová, Andrea, Csejtei, András, Gábor, Gabriella, Landherr, László, Mangel, László, Mayer, Árpád, Fodor, János

“…The international radiotherapy (RT) expert panel has revised and updated the RT guidelines that were accepted in 2020 at the 4th Hungarian Breast Cancer…”
Get full text

Pathologic Complete Response Rates After Neoadjuvant Pertuzumab and Trastuzumab with Chemotherapy in Early Stage HER2-Positive Breast Cancer - Increasing Rates of Breast Conserving Surgery: A Real-World Experience by Boér, Katalin, Kahán, Zsuzsanna, Landherr, László, Csőszi, Tibor, Máhr, Károly, Ruzsa, Ágnes, Horváth, Zsolt, Budai, Barna, Rubovszky, Gábor

“…The neoadjuvant use of pertuzumab and trastuzumab with chemotherapy improves the pathologic complete response (pCR) in early HER2+ breast cancer. The aim of…”
Get full text

An open‐label, dose‐ranging study of Rolontis, a novel long‐acting myeloid growth factor, in breast cancer by Vacirca, Jeffrey L., Chan, Arlene, Mezei, Klára, Adoo, Clarence S., Pápai, Zsuzsanna, McGregor, Kimberly, Okera, Meena, Horváth, Zsolt, Landherr, László, Hanslik, Jerzy, Hager, Steven J., Ibrahim, Emad N., Rostom, Makharadze, Bhat, Gajanan, Choi, Mi Rim, Reddy, Guru, Tedesco, Karen L., Agajanian, Richy, Láng, István, Schwartzberg, Lee S.

“…This randomized, open‐label, active‐controlled study investigated the safety and efficacy of three doses of Rolontis (eflapegrastim), a novel, long‐acting…”
Get full text

The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2−) breast cancer: When might multigene assays be of value? by Aapro, Matti, De Laurentiis, Michelino, Rea, Dan, Bargallo Rocha, Juan Enrique, Elizalde, Roberto, Landherr, László, Linderholm, Barbro, Mamounas, Eleftherios, Markopoulos, Christos, Neven, Patrick, Petrovsky, Alexander, Rouzier, Roman, Smit, Vincent, Svedman, Christer, Schneider, Daniel, Thomssen, Christoph, Martin, Miguel

“…Abstract Background A modest proportion of patients with early stage hormone receptor-positive (HR+), HER2-negative (HER2−) breast cancer benefit from adjuvant…”
Get full text

Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study by Kószó, Renáta, Sántha, Dóra, Büdi, László, Erfán, József, Győrfy, Károly, Horváth, Zsolt, Kocsis, Judit, Landherr, László, Hitre, Erika, Máhr, Károly, Pajkos, Gábor, Pápai, Zsuzsanna, Kahán, Zsuzsanna

“…Due to the limited experience with capecitabine plus docetaxel (XT) combination in the first-line treatment of metastatic breast cancer in Hungary, the main…”
Get full text

Vitamin D and breast cancer by Nagykálnai, Tamás, Landherr, László, Nagy, András Csaba

“…The active form of vitamin D, in conjunction with his own receptor, affect a multitude of biological processes in the cell (inter alia it influences the…”
Get more information

Postoperative radiotherapy of breast cancer and cardiotoxicity by Nagykálnai, Tamás, Nagy, A Csaba, Landherr, László

“…Cardiac complications may present a particular problem following radiation treatment applied to the mediastinum and thoracic wall (and especially to the left…”
Get more information

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study by Burtness, Barbara, Greil, Richard, de Castro, Gilberto, Fuereder, Thorsten, Ngamphaiboon, Nuttapong, Wan Ishak, Wan Zamaniah, Hong, Ruey-Long, González Mendoza, René, Zhang, Yayan, Gumuscu, Burak, Boyer, Michael, Hughes, Brett, Rischin, Danny, Taylor, Anne, Burian, Martin, Barrios, Carlos Henrique, de Castro Junior, Dalvaro Oliveira, Franke, Fabio Andre, Girotto, Gustavo, Lima, Iane Pinto Figueiredo, Nicolau, Ulisses Ribaldo, Santos, Lucas, Victorino, Ana-Paula, Chua, Neil, Couture, Felix, Hansen, Aaron, Hilton, John, McCarthy, Joy, Soulieres, Denis, Ascui, Rodrigo, Villanueva, Luis, Kral, Zdenek, Prausova, Jana, Vosmik, Milan, Jurgens, Hannes, Putnik, Kadri, Gruenwald, Viktor, Boukovinas, Ioannis, Psyrri, Amanda, Kwong, Dora, Csoszi, Tibor, Horvai, Geza, Landherr, Laszlo, Szota, Judit, Billan, Salem, Nole, Franco, Fujimoto, Yasushi, Hanai, Nobuhiro, Hara, Hiroki, Shimizu, Yasushi, Sugasawa, Masashi, Takahashi, Shunji, Tanaka, Kaoru, Ueda, Tsutomu, Wan Ishak, Wan Zamaniah, Gonzalez Mendoza, Rene, Buter, Jan, Hoeben, Ann, Bratland, Aase, Querol, John, Regala, Eugenio Emmanuel, Villegas, Ellie May, Karpenko, Andrey, Zarubenkov, Oleg, Cohen, Graham, du Toit, Johanna, Jordaan, Christa, Landers, Gregory, Ruff, Paul, Tabane, Neonyana, Brana, Irene, Iglesias Docampo, Lara, Abel, Edvard, Muratidu, Valentina, Nielsen, Niels, Cristina, Valerie, Rothschild, Sacha, Yang, Muh-Hwa, Yeh, Su-Peng, Ngamphaiboon, Nuttapong, Cicin, Irfan, Ekenel, Meltem, Harrington, Kevin, Ali, Haythem, Anderson, Daniel, Bruce, Justine, Halmos, Balazs, Hegde, Upendra, Khan, Saad, Martincic, Danko, McCune, Steven, Misiukiewicz, Krzysztof, Neupane, Prakash, Nunnink, Johannes, O'Malley, Meaghan, Powell, Steven, Redman, Rebecca, Rella, Vincent, Rocha Lima, Chaio, Wong, Stuart

“…Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved…”
Get full text

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study by Cohen, Ezra E W, Soulières, Denis, Le Tourneau, Christophe, Dinis, José, Licitra, Lisa, Ahn, Myung-Ju, Soria, Ainara, Mach, Nicolas, Mehra, Ranee, Burtness, Barbara, Zhang, Pingye, Cheng, Jonathan, Swaby, Ramona F, Acosta-Rivera, Mirelis, Adkins, Douglas R., Aghmesheh, Morteza, Ahn, Myung-Ju, Airoldi, Mario, Aleknavicius, Eduardas, Al-Farhat, Yousuf, Algazi, Alain P., Almokadem, Salah, Alyasova, Anna, Bauman, Jessica R., Benasso, Marco, Berrocal, Alfonso, Bray, Victoria, Burtness, Barbara Ann, Caponigro, Francesco, Castro, Ana, Cescon, Terrence P., Chan, Kelvin, Chaudhry, Arvind, Chauffert, Bruno, Cohen, Ezra, De Boer, J.P., Dietz, Andreas, Dinis, Jose, Dupuis, Charlotte, Digue, Laurence, Escobar Alvarez, Yolanda, Evans, Mererid, Fidler, Mary Jo, Forster, Martin David, Friesland, Signe, Ganti, Apar K., Geoffrois, Lionnel, Grant, Cliona, Gruenwald, Viktor, Harrington, Kevin, Horvai, Geza, Inciura, Arturas, Jang, Raymond, Jankowska, Petra, Jimeno, Antonio, Joseph, Mano, Juarez Ramiro, Alejandro, Karaszewska, Boguslawa, Kawecki, Andrzej, Keilholz, Ulrich, Keller, Ulrich, Kocsis, Judit, Kotecki, Nuria, Kozloff, Mark F., Lambea, Julio, Landherr, Laszlo, Lantsukhay, Yuri, Lazarev, Sergey Alexandrovich, Lee, Lip Way, Le Tourneau, Christophe, Licitra, Lisa, Martincic, Danko, Matorin, Oleg Vladmirovhich, McGrath, Margaret, Machiels, Jean-Pascal, Mehra, Ranee, Misiukiewicz, Krzysztof, Morris, John C., Mufazalov, Fagim Fanisovich, Niu, Jiaxin, Pamoorthy Srinivasan, Devraj, Perez Segura, Pedro, Rauch, Daniel, Ribeiro, Maria Leonor, Rodriguez, Cristina, Rolland, Frederic, Russo, Antonio, Ruzsa, Agnes, Sanches, Frederico, Shin, Sang-Won, Shtiveland, Mikhail, Soulieres, Denis, Specenier, Pol, van Herpen, Carla M.L., Velez-Cortes, Hector A., Walsh, William V., Winterhalder, Ralph, Wojtukiewicz, Marek, Wong, Deborah, Zandberg, Dan

“…There are few effective treatment options for patients with recurrent or metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour…”
Get full text

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial by Siefker-Radtke, A O, Matsubara, N, Park, S H, Huddart, R A, Burgess, E F, Özgüroğlu, M, Valderrama, B P, Laguerre, B, Basso, U, Triantos, S, Akapame, S, Kean, Y, Deprince, K, Mukhopadhyay, S, Loriot, Y

“…Erdafitinib is an oral pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor approved to treat locally advanced/metastatic urothelial…”
Get more information

First-line bevacizumab-paclitaxel in 220 patients with metastatic breast cancer: results from the AVAREG study by Dank, Magdolna, Budi, Laszlo, Piko, Bela, Mangel, Laszlo, Erfan, Jozsef, Cseh, Jozsef, Ruzsa, Agnes, Landherr, Laszlo

“…First-line bevacizumab-paclitaxel therapy demonstrated a median progression-free survival (PFS) of 11 months in three randomized phase III trials on metastatic…”
Get full text

Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study by Jerusalem, Guy Heinrich Maria, Kovalenko, Elena, Yardley, Denise A., De Boer, Richard H., Hurvitz, Sara A., Ejlertsen, Bent, Blau, Sibel, Ozguroglu, Mustafa, Landherr, Laszlo, Ewertz, Marianne, Taran, Tanya, Fan, Jenna, Noel-Baron, Florence, Louveau, Anne-Laure, Burris, Howard A.

“…Abstract only…”
Get full text

Efficacy and safety of first-line bevacizumab combined with paclitaxel in 220 patients with metastatic breast cancer: The Hungarian AVAREG observational study by Dank, Magdolna, Budi, Laszlo, Landherr, Laszlo, Piko, Bela, Mangel, Laszlo, Erfán, Jozsef, Cseh, Jozsef, Ruzsa, Agnes, Nagy, Andras

“…Abstract only e12022^ Background: First-line bevacizumab (Bev) combined with paclitaxel (Pac) significantly improves progression-free survival (PFS) and…”
Get full text

Abstract P3-19-24: Long-term follow-up results of intensity modulated radiotherapy in early-stage breast cancer patients by Zolcsák, Zita, Loap, Pierre, Fourquet, Alain, Henry, Alexandre Arsene, Landherr, László, Hamar, Péter, Kirova, Youlia

“…Introduction: Early breast cancer patients with complex anatomy received adjuvant intensity modulated radiotherapy with helical tomotherapy (IMRT-HT) in our…”
Get full text

Predictive and prognostic factors in the complex treatment of patients with colorectal cancer by László, Landherr

“…Colon cancer is the second most prevalent lethal cancer. The main cause for high mortality rate is that the prognosis for progressed metastatic colon cancer is…”
Get more information

Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial by Tempero, Margaret A, Pelzer, Uwe, O'Reilly, Eileen M, Winter, Jordan, Oh, Do-Youn, Li, Chung-Pin, Tortora, Giampaolo, Chang, Heung-Moon, Lopez, Charles D, Bekaii-Saab, Tanios, Ko, Andrew H, Santoro, Armando, Park, Joon Oh, Noel, Marcus S, Frassineti, Giovanni Luca, Shan, Yan-Shen, Dean, Andrew, Riess, Hanno, Van Cutsem, Eric, Berlin, Jordan, Philip, Philip, Moore, Malcolm, Goldstein, David, Tabernero, Josep, Li, Mingyu, Ferrara, Stefano, Le Bruchec, Yvan, Zhang, George, Lu, Brian, Biankin, Andrew V, Reni, Michele

“…This randomized, open-label trial compared the efficacy and safety of adjuvant -paclitaxel + gemcitabine with those of gemcitabine for resected pancreatic…”
Get full text

Complex treatment of hepatocellular carcinoma Consensus Conference, Budapest, April 24, 2021

Get more information

Management of bone metastases by Nagykálnai, Tamás, Landherr, László

“…The skeleton is the most common site to be affected by advanced breast, prostatic, lung, kidney, thyroid and other solid tumors (in addition to myeloma…”
Get more information

The role of PET/CT in decision-making during cancer treatment. Clinical experience by Sinkó, Dániel, Landherr, László

“…Nowadays PET/CT examinations have got more and more important role during cancer treatment. It has importance not only in diagnostic examination and staging…”
Get more information

Abstract P6-08-06: The multidisciplinary application of genomics in clinical practice (MAGIC) survey: Identification of early stage hormone receptor-positive (HR+), HER2– breast cancer (BC) patients for whom multigene assays may be valuable by Aapro, Matti, Bargallo Rocha, Juan Enrique, De Laurentiis, Michele, Elizalde, Roberto, Landherr, László, Linderholm, Barbro, Mamounas, Terry, Markopoulos, Christos, Martin, Miguel, Neven, Patrick, Petrovsky, Alexander, Rea, Dan, Rouzier, Roman, Smit, Vincent, Svedman, Christer, Thomssen, Christoph

“…Background Treatment recommendations for early stage HR+, HER2– BC patients depend on many factors. The MAGIC survey evaluated which criteria clinicians use…”
Get full text